文献速递消化道肿瘤与早癌消化内镜

在两项现有筛查项目中附加血液结直肠癌筛查试验的诊断准确性

Diagnostic Accuracy of an Add-On, Blood-Based Screening Test for Colorectal Cancer in Two Established Screening Programmes.
PubMed 文献 · Aliment Pharmacol Ther · 2025-04-10

本研究为前瞻性研究,纳入809名粪便免疫化学试验(FIT)阳性筛查者,评估CELTiC血液检测作为附加试验检测进展期肿瘤(AN)的诊断准确性。CELTiC在预设阈值下未达到90%灵敏度(组I 41%,组II 27%);在事后阈值达到90%灵敏度时,组I特异度14%(53/388),组II特异度12%(44/354)。结论认为目前不推荐CELTiC作为FIT阳性筛查者的附加检测。

要点

  • CELTiC在预设阈值下灵敏度未达90%:组I 41%,组II 27%。
  • 事后阈值达90%灵敏度时特异度低:组I 14%,组II 12%。
  • 目前不推荐CELTiC作为FIT阳性筛查者的附加检测。

核心结论

  • 在FIT阳性人群中,CELTiC在预设阈值下未达到90%灵敏度,在事后阈值下特异度低,目前不能推荐作为CRC筛查项目中检测AN的附加试验。

研究设计与样本

  • 前瞻性研究,纳入FIT阳性筛查者809人,分析两组部分重叠人群:组I为FIT≥47 μg Hb/g粪便(n=567),组II为FIT≥20 μg Hb/g粪便(n=486)。

主要发现

  • CELTiC在预设阈值下检测AN的灵敏度:组I 41%,组II 27%。
  • 在事后阈值达到90%灵敏度时,CELTiC检测AN的特异度:组I 14%(53/388;95% CI:10%至17%),组II 12%(44/354;95% CI:9%至16%)。

关键数值与推荐

  • CELTiC由四种mRNA(CEACAM6、LGALS4、TSPAN8和COL1A2)组成,与结直肠癌相关。
  • 预设目标灵敏度为90%。
  • 事后阈值设定为使检测AN的灵敏度达到90%。

临床怎么用

  • 原文结论指出目前不能推荐CELTiC作为FIT阳性筛查者中检测AN的附加试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: CELTiC is a blood-based test consisting of a panel of four mRNAs (CEACAM6, LGALS4, TSPAN8 and COL1A2) associated with colorectal cancer (CRC). CELTiC has a high sensitivity (90%) for detecting advanced neoplasia (AN) when compared to faecal immunochemical test (FIT)-negative subjects. AIMS: To evaluate the diagnostic accuracy of CELTiC as an add-on test following a positive FIT in two existing CRC screening programmes. METHODS: We designed a prospective study in FIT-positive screenees. Analyses were performed in two (partially overlapping) groups: participants with FIT ≥ 47 μg Hb/g faeces (group I) and FIT ≥ 20 μg Hb/g faeces (group II). We estimated CELTIC sensitivity and specificity in detecting AN at a pre-defined and a post hoc threshold (targeted sensitivity: 90%). RESULTS: We included 809 participants (n = 567 in group I and n = 486 in group II). CELTiC did not reach a sensitivity of 90% at the pre-defined threshold (Group I 41%, group II 27%). At the post hoc thresholds for 90% sensitivity in detecting AN, CELTiC had a specificity of 14% (53/388; 95% CI: 10% to 17%) in group I and 12% (44/354; 95% CI: 9% to 16%) in group II. CONCLUSIONS: In a FIT-positive population, CELTiC did not reach 90% sensitivity at the pre-defined threshold. At post hoc thresholds corresponding to 90% sensitivity, specificity was low. CELTiC cannot currently be recommended as an add-on test to detect AN in FIT-positive screenees in a CRC screening programme. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04980443, NCT05205967, NCT04369053.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kortlever TL, Ferlizza E, Lauriola M, et al. Diagnostic Accuracy of an Add-On, Blood-Based Screening Test for Colorectal Cancer in Two Established Screening Programmes. Aliment Pharmacol Ther. 2025. PMID: 40207404. doi:10.1111/apt.70141

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。